The frequency of hypoglycemia development depended on the type of baseline therapy used in each study. The studies dapagliflozin as a monotherapy, combination therapy is trenbolone legal with metformin for up to 102 weeks, the incidence of mild hypoglycemia episodes was similar in the treatment groups, including placebo. In all studies, episodes of severe hypoglycemia observed infrequently, and their incidence was comparable between dapagliflozin and placebo group.
The decrease of the bcc Adverse reactions associated with a decrease in the bcc (including reports of dehydration, hypovolemia or hypotension), were observed of patients treated with dapagliflozin 10 mg and placebo, respectively; serious reactions were reported in <0.2% of patients and were comparable between groups dapagliflozin 10 mg, and placebo (see. “Special Instructions” section). Vulvovaginitis, balanitis and genital infections such trenbolone side effects, balanitis and similar genital infections were observed in 4.8% and 0.9% of patients treated with dapagliflozin 10 mg and placebo, respectively. Most infections were mild or moderate; initial course of standard therapy was effective, and therefore patients rarely stopped receiving dapagliflozin. These infections usually develop in women (6.9% and 1.5% with dapagliflozin and placebo, respectively), and in patients with a history of such infections, they often recur.
Urinary Tract Infections Urinary tract infections frequently observed in the application of dapagliflozin 10 mg than with placebo (4.3% compared with 3.7%, respectively, see “Special instructions” section.). Most infections were mild or moderate; initial course of standard therapy was effective, and therefore patients rarely discontinued use of dapagliflozin. These infections usually develop in women and in patients with a history of such infections, they often recur. Parathyroid hormone trenbolone side effects noted a slight increase in serum concentrations, and to a greater extent in patients with higher baseline concentrations of PTH. Studies of bone mineral density in patients with normal renal function or impaired renal function have not revealed mild bone loss within one year of therapy.
Malignancies In clinical studies, the overall proportion of patients with malignant or unspecified tumors was similar in the group of dapagliflozin (1.47 %) and the placebo / comparator product (1.35%).According to animal studies the drug did not show carcinogenic or mutagenic properties. When considering the incidence of tumors of various organ systems, the relative risk associated with dapagliflozin was above 1 for certain cancers (bladder, prostate gland, mammary gland) and less than 1 for the other (for example, blood and lymphatic system, ovaries, urinary system) generally without increasing the cancer risk associated with dapagliflozin. Increase / decrease the risk was not statistically significant for either one organ system. Given the lack of preclinical data on the development of tumors, as well as a short latency period between the first drug exposure and tumor diagnosis, causal relationship is assessed as unlikely. Since the numerical imbalance of breast tumors, bladder and prostate requires special attention, the study of this issue will continue in the framework trenbolone side effects of post-marketing studies. Elderly patients ( > 65 years) Adverse reactions associated with impaired renal function or renal insufficiency, reported in 2, 5% of patients receiving dapagliflozin, and in 1.1% of patients receiving placebo, in patients > 65 years (see. “Special instructions” section). The most common adverse reactions associated with renal dysfunction, were increased creatinine concentration in the serum. Most of these reactions were transient and reversible. Among patients aged > 65 years, reduction of BCC, the most frequently reported as arterial hypotension was seen in 1.5% and 0.4% of patients taking dapagliflozin and placebo groups, respectively (see. “Special Instructions” section)